Literature DB >> 9882352

Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions.

M Dettenhofer1, X F Yu.   

Abstract

The vif gene of human immunodeficiency virus type 1 (HIV-1) is essential for the productive infection of primary blood-derived lymphocytes, macrophages, and certain human T-cell lines. It has been shown that Vif is associated with HIV-1 virions purified by sucrose density-equilibrium gradient analysis. However, the specificity of Vif incorporation into virions has not been determined. Moreover, recent studies have demonstrated that standard HIV-1 particle preparations created with sucrose density-equilibrium gradients are contaminated with cell-derived microvesicles. Here we demonstrate, as previously reported, that Vif cosediments with HIV-1 particles in sucrose density-equilibrium gradient analysis. However, we also found that, when Vif was expressed in the absence of all other HIV-1-encoded gene products and then isolated by sucrose density-equilibrium gradient centrifugation from extracellular supernatants, its sedimentation pattern was largely unaltered, suggesting that Vif can be secreted from cells. Using a newly developed OptiPrep velocity gradient method, we were able to physically separate most of the extracellular Vif from the HIV-1 virions without disrupting the infectivity of the virus. By titrating serial dilutions of purified Vif and Gag against the viral peak fraction in the OptiPrep gradient, we demonstrate that <1.0 Vif molecule per virion was present. This study shows that Vif is not significantly present in HIV-1 virions, a finding which is consistent with the idea that Vif functions predominantly in the virus-producing cells during virus assembly. The OptiPrep velocity gradient technique described here could be an easy and rapid way to purify HIV and other enveloped viruses from microvesicles and/or cell debris.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882352      PMCID: PMC103971     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.

Authors:  M K Karczewski; K Strebel
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.

Authors:  A M Borman; C Quillent; P Charneau; C Dauguet; F Clavel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

4.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.

Authors:  E O Freed; M A Martin
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes.

Authors:  M Simm; M Shahabuddin; W Chao; J S Allan; D J Volsky
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain.

Authors:  D E Ott; L V Coren; D G Johnson; R C Sowder; L O Arthur; L E Henderson
Journal:  AIDS Res Hum Retroviruses       Date:  1995-09       Impact factor: 2.205

10.  The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.

Authors:  H Liu; X Wu; M Newman; G M Shaw; B H Hahn; J C Kappes
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  105 in total

1.  Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein.

Authors:  O Lenz; J ter Meulen; H Feldmann; H D Klenk; W Garten
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  N-terminal cleavage fragment of glycosylated Gag is incorporated into murine oncornavirus particles.

Authors:  R Fujisawa; F J McAtee; C Favara; S F Hayes; J L Portis
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution.

Authors:  Florian K M Schur; Wim J H Hagen; Michaela Rumlová; Tomáš Ruml; Barbara Müller; Hans-Georg Kräusslich; John A G Briggs
Journal:  Nature       Date:  2014-11-02       Impact factor: 49.962

Review 5.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

6.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  The cellular protein lyric interacts with HIV-1 Gag.

Authors:  Christine E Engeland; Heike Oberwinkler; Michael Schümann; Eberhard Krause; Gerd A Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 8.  Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles: Current status and future directions.

Authors:  Shima Gholizadeh; Mohamed Shehata Draz; Maryam Zarghooni; Amir Sanati-Nezhad; Saeid Ghavami; Hadi Shafiee; Mohsen Akbari
Journal:  Biosens Bioelectron       Date:  2016-12-30       Impact factor: 10.618

9.  Lipid biosensor interactions with wild type and matrix deletion HIV-1 Gag proteins.

Authors:  Eric Barklis; August O Staubus; Andrew Mack; Logan Harper; Robin Lid Barklis; Ayna Alfadhli
Journal:  Virology       Date:  2018-03-15       Impact factor: 3.616

10.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.